Lexicon Pharmaceuticals Inc., of The Woodlands, Texas, reported preliminary results from a Phase I dose-ranging study of LX2931, an inhibitor of sphingosine-1-phosphate lyase, in rheumatoid arthritis. The compound was well tolerated at all doses evaluated, with no serious adverse events.
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter